ClinicalTrials.gg
RecruitingNCT06639113AUTOGESTMEDUpdated Oct 20, 2026

From Administration of Oral Medicines by Nurses to Controlled Self-administration: Impact on Safety of Administration During Hospitalisation

An interventional study of Self-administration medicines in Self Administration, sponsored by Centre Hospitalier de Valenciennes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Centre Hospitalier de Valenciennes · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2024, registered Sep 2024).
  • Started May 2024; still recruiting 2 years 5 months later.
Updated Oct 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Medication administration practices during patient hospital stay tend to improve patient autonomy. Several studies have concluded that self-administration of medication programs in hospital centers have a beneficial effect on patients' knowledge of their medications, their compliance and the safety of administration. Nevertheless, few studies have been carried out in France on this subject. The aim of this study is to evaluate the impact of the change of nurses administration practices from the administration of each drugs to supervision of self-administration by the patient under a self-administration program.

02

Conditions studied

  • Self Administration

Keywords

  • Rehabilitation
  • Self-management of medication
  • Administration
  • Autonomy
03

In context

Lead sponsor

Centre Hospitalier de Valenciennes is the lead sponsor of 15 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Care in the rehabilitation unit of Hospital in Valenciennes, France
  • Patient with a planned stay of 7 days or more
  • Patient on chronic treatment before admission to hospital ;
  • Patients taking their treatment alone at home;

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years old
  • Patients with poor compliance
  • No chronic treatment
  • Unstable disease
  • Major cognitive, memory or depressive disorders
  • Swallowing disorders
  • Prehension problems
  • Patient under legal protection
  • Patient under guardianship or curatorship
  • Patient included in another trial
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    Self administration of medication by the patient

    Self administration of medication by the patient

    Behavioral: Self-administration medicines

  • No intervention
    Administration of medication by the nurses

    Administration of medication by the nurses during medication administration rounds

Interventions

  • BehavioralSelf-administration medicines

    Management of drugs' administration by the patient

06

What researchers measure

Primary outcomes

  1. Total number of oral medication administration errors in self-administered patients

    Total number of oral medication administration errors in self-administered patients

    Time frame: After 7 days of self-administration

  2. Total number of oral medication administration errors in patients receiving administration by nurses

    Total number of oral medication administration errors in patients receiving administration by nurses

    Time frame: After 7 days of administration by nurses

Secondary outcomes

  1. Medication compliance in self-managed patients

    Medication compliance is assessed using the questionnaire "Evaluation of medication compliance" provided by the French health insurance system. This questionnaire consists of 6 questions with "yes" or "no" answers. Each "no" answer is worth 1 point, each "yes" answer is worth 0 points. A patient with poor medication compliance will have a score of 3 or less.

    Time frame: At the beginning of the study

  2. Medication compliance in self-managed patients

    Medication compliance is assessed using the questionnaire "Evaluation of medication compliance" provided by the French health insurance system. This questionnaire consists of 6 questions with "yes" or "no" answers. Each "no" answer is worth 1 point, each "yes" answer is worth 0 points. A patient with poor medication compliance will have a score of 3 or less.

    Time frame: 15 days after hospital discharge for self-managed patients

  3. Patient satisfaction with self-administration of oral medication

    Patient satisfaction was assessed using a questionnaire designed by the investigator, consisting of 9 questions giving a total of 45 points. The higher the total, the higher the level of satisfaction.

    Time frame: Within 24 hours of discharge from hospital

  4. Care staff satisfaction with self-administration

    Care staff satisfaction was assessed using a questionnaire designed by the investigator, consisting of 4 questions totalling 20 points. The higher the total, the higher the level of satisfaction.

    Time frame: 6 months after the beginning of the study

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion May 2026 → May 2027 and completion May 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Oct 15, 2024
StartActual
May 24, 2024
Primary completionEst.
May 2027was May 2026
CompletionEst.
Jun 2027was May 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2026→May 2027
Oct 20, 2026
Study completion
May 2026→Jun 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion May 2026→May 2027
    Study completion May 2026→Jun 2027
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06639113
Lead sponsor
Centre Hospitalier de Valenciennes
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
May 24, 2024
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Quentin HIVER
Contact
hiver-q@ch-valenciennes.fr
0327143333
Quentin HIVER, PH
principal investigator · Centre Hospitalier de Valenciennes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion